1900–1925
DTP EVOLUTION —
high bandwidth | low
bandwidth | transcript
1926–1950
Mechlorethamine, ethinyl estradiol, TEM, mercaptopurine, methotrexate, busulfan
1955
Mouse L1210 leukemia model, screening of up to 40K per year
1957
1962
1967
Chemical Abstracts Service (CAS) contract begins
1968
1969
TAXOL — high
bandwidth | low
bandwidth | transcript
1970
Multimodal therapy proven more effective than surgery alone in some cancers
1971
War on cancer declared by President Nixon
1975
Mouse P388 model adopted as primary screen
Input at 15,000 per year
Rational selection approach used
1976
1977
1978
Biological Response Modifiers Program planning begins
Average cost of preclinical development is $215,000
200 companies have signed discreet agreement
CISPLATIN — high
bandwidth | low bandwidth
| transcript
1979
Linear array becomes standard approach
1980
17-AAG 330507 (Geldanamycin analog) received
Cures against leukemias possible
Lacking effective drugs for solid tumors in general
1981
Hodes model for ranking small molecule structures
1982
Mix of mouse and human tumors
TUMOR PANEL — high
bandwidth | low bandwidth
| transcript
1983
1984
Taxol 125973 clinical trials begin
DTP produces 1,000,000 injectable units per year
1985
Drug Information System (DIS) developed
Chemical Abstracts Service (CAS) contract ends
1986
Halichondrin B 609395 received
1989
1990
Human tumor cell line assay adopted as primary screen
Erbitux 632307 NCDDG begins work
1991
Natural products repository makes extracts available to researchers
Depsipeptide 630176 presented to DN
FLUDARABINE — high
bandwidth | low bandwidth
| transcript
1992
Human tumor cell line panel revised to include breast and prostate cell lines
Geldanamycin 122750 presented to DN
Flavopiridol 649890 received and presented to DN
Halichondrin B 609395 presented to DN
1994
Benzothiazole 674495 parent received
Flavopiridol 649890 clinical trials begin
FLAVOPIRIDOL 649890 —
high bandwidth
| low bandwidth
| transcript
1995
Hollow fiber assay adopted as prerequisite for xenograft studies
Biological Resources Branch integrated into DTP
1996
Benzothiazole 674495 parent presented to DN
Depsipeptide 630176 clinical trials begin
BCNU 409962 (Gliadel Wafer) developed by NCDDG
Yeast screening program begins at Fred Hutchinson Cancer Research Center
1997
Velcade 681239 presented to DN
Aminoflavone 686288 presented to DN
1998
Mouse Models of Human Cancers Consortium
17-DMAG 707545 (Geldanamycin analog) received
E7389 707389 (Halichondrin B analog) presented to DN
Emphasis on extramural support
"Open" repository of compounds created
Input down to 3K in favor of molecular targets emphasis
1999
Epothilone 703147 RAID project approved
BL22 691237 clinical trial begins
Velcade 681239 clinical trials begin
Benzothiazole prodrug 710305 received
Aminoflavone prodrug 710464 received
SJG-136 694501 presented to DN
17-AAG 330507 clinical trials begin
E7 Vaccine 723254 RAID project approved
2000
Dynamic Molecular Targets Website launched, including first microarray data
Decision Network (DN) changed to Drug Development Group (DDG)
2001
Epothilone 703147 clinical trials begin
Screening of 140,000 compounds in yeast screen completed
R*A*N*D and IIP initiatives begin
2002
Phortress 710305 (Benzothiazole prodrug) presented to DDG
17-DMAG 707545 presented to DDG
E7389 707389 clinical trials begin
Aminoflavone prodrug 710464 presented to DDG
2003
SJG-136 694501 clinical trials begin
Velcade 681239 receives NDA for multiple myeloma
Phortress 710305 in clinical trials in the United Kingdom
E7 Vaccine 723254 clinical trials begin
2004
Academic Public Private Partnership Program (AP4) planning grants funded
17-DMAG 707545 clinical trials begin
2005
Aminoflavone prodrug 710464 clinical trials begin
DTP's 50th anniversary
2006
Reinventing drug development at NCI: PK/PD
2015
FUTURE OF DTP — high
bandwidth | low
bandwidth | transcript
NCI CHALLENGE GOAL —
high bandwidth
| low bandwidth |
transcript
